Methods: This was a retrospective, observational, single center study performed at a large
community teaching hospital. Patients were stratified into three groups based on time of CT …

Purpose The change in turnaround time of 4-factor prothrombin complex concentrate (PCC)
when managed by the pharmacy department compared to blood bank management was …

Aim Hemostatic management of patients on oral anticoagulant therapy with critical bleeding
continues to be a major challenge. The present study aimed to validate the efficacy, safety …

Objective: To review the evidence supporting the use of prothrombin complex concentrate
(PCC) as a hemostatic agent in individuals without hemophilia. Data Sources: Articles were …

Background: Intracranial haemorrhage (ICH) is a serious and potentially fatal complication
of oral anticoagulant therapy (OAT). Prothrombin complex concentrates (PCCs) produce a …

We report our initial experience using Profilnine SD, a 3-Factor prothrombin complex
concentrate (PCC) in combination with fresh frozen plasma and vitamin K in seven patients …

Prothrombin complex concentrates (PCCs) are indicated for urgent reversal of warfarin and
used for reversal of novel oral anticoagulants, in patients with acute major bleeding or need …

Objective Four-factor prothrombin complex concentrate (4F-PCC) was approved by the US
Food and Drug Administration in 2013 for management of severely bleeding patients on …

Introduction Four-factor prothrombin complex concentrate (4F-PCC) may be an option for
patients with bleeding unrelated to therapeutic anticoagulation to help with bleeding …

Methods: Consecutive patients over a two-year period that received more than one PCC
dose for life-threatening bleeding were retrospectively evaluated. Two observed re-dosing …